Celularity Inc.(CELU)Earnings, Financials & Key Ratios

CELU•NASDAQ

$0.80

Price updated Jul 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCell and Gene Therapy Developers

AboutCelularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.Show more

Revenue$27M-51.0%
EBITDA-$54M-77.5%
Net Income-$92M-58.6%
EPS (Diluted)-3.59-35.7%
Gross Margin76.04%+5.1%
EBITDA Margin-203.44%-262.4%
Operating Margin-230.92%-226.4%
Net Margin-345.76%-223.8%

CELU Price & Volume

Celularity Inc. (CELU) stock price & volume — 10-year historical chart

Loading chart...

Severe Liquidity Constraints Threaten Celularity Operational Viability

Investment Thesis • Updated 2025Q4

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity and insolvency

Key Thesis Takeaways

Celularity faces a critical inflection point as its core revenue streams have contracted by 77.4% year-over-year, leaving the company with an unsustainable cost structure where SG&A expenses of $15.1M vastly outweigh quarterly revenue of $4.1M.
The firm's reliance on stock-based compensation to mask cash burn, combined with a negative equity position of $38.1M, suggests an imminent risk of insolvency.
Investors should monitor the company's ability to secure external capital, as the current liquidity profile with a 0.15 current ratio appears insufficient to support ongoing clinical research.

Verdict Logic

the company's current ratio of 0.15 and a $38.1M equity deficit indicate a high probability of near-term liquidity failure and potential shareholder dilution.

CELU Growth Metrics

Celularity Inc. (CELU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years13.21%

3 Years13.88%

TTM-51.03%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-58.42%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-39.22%

Return on Capital

10 Years-61.66%

5 Years-58.51%

3 Years-86%

Last Year-116.14%

Peers Comparison

Key metrics vs top competitors for Celularity Inc. (CELU)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
CELUCelularity Inc.Current	$0.80	$19.24M	-0.22	-51.03%	-345.76%	—	28.81%
FATEFate Therapeutics, Inc.	$2.99	$348.51M	-2.60	-51.24%	-2056.79%	-58.89%	—
NKTRNektar Therapeutics	$73.15	$1.43B	-7.52	-43.89%	-284.18%	-87%	—
SANASana Biotechnology, Inc.	$3.97	$1.1B	-4.14	—	—	-161.87%	—
ALLOAllogene Therapeutics, Inc.	$2.09	$509.69M	-2.40	-100%	—	-56.45%	—
CRSPCRISPR Therapeutics AG	$61.89	$5.97B	-9.57	-89.97%	-13856.54%	-30.88%	—